Sio Capital Management LLC Sells 9,341 Shares of Biodesix, Inc. (NASDAQ:BDSX)

Sio Capital Management LLC reduced its holdings in shares of Biodesix, Inc. (NASDAQ:BDSX) by 0.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,338,514 shares of the company’s stock after selling 9,341 shares during the period. Biodesix accounts for approximately 3.1% of Sio Capital Management LLC’s investment portfolio, making the stock its 12th biggest holding. Sio Capital Management LLC owned approximately 2.98% of Biodesix worth $7,723,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BDSX. CVI Holdings LLC acquired a new stake in Biodesix during the second quarter worth approximately $59,000. Landscape Capital Management L.L.C. acquired a new stake in shares of Biodesix during the 3rd quarter worth approximately $262,000. Perkins Capital Management Inc. grew its position in shares of Biodesix by 74.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock worth $1,290,000 after buying an additional 310,000 shares during the period. Farallon Capital Management LLC bought a new stake in shares of Biodesix in the 2nd quarter valued at $2,874,000. Finally, Perceptive Advisors LLC acquired a new position in shares of Biodesix during the 2nd quarter valued at $3,326,000. 20.96% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Biodesix

In other news, Director Jack W. Schuler bought 200,000 shares of the stock in a transaction dated Wednesday, November 20th. The stock was bought at an average price of $1.17 per share, for a total transaction of $234,000.00. Following the completion of the acquisition, the director now directly owns 31,094,935 shares in the company, valued at approximately $36,381,073.95. This trade represents a 0.65 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Chairman John Patience purchased 75,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were purchased at an average price of $1.38 per share, for a total transaction of $103,500.00. Following the completion of the acquisition, the chairman now owns 2,153,298 shares of the company’s stock, valued at $2,971,551.24. The trade was a 3.61 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 315,000 shares of company stock valued at $393,500. 69.20% of the stock is owned by corporate insiders.

Biodesix Stock Down 0.7 %

Shares of NASDAQ:BDSX opened at $1.43 on Friday. Biodesix, Inc. has a twelve month low of $1.11 and a twelve month high of $2.21. The stock’s 50 day moving average is $1.54 and its 200-day moving average is $1.61. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings data on Friday, November 1st. The company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $18.15 million for the quarter, compared to the consensus estimate of $18.45 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. During the same quarter in the prior year, the company posted ($0.12) earnings per share. As a group, equities research analysts predict that Biodesix, Inc. will post -0.35 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Scotiabank assumed coverage on shares of Biodesix in a report on Monday, September 16th. They issued a “sector outperform” rating and a $3.00 price target for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $3.06.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.